|
1
|
Chen W, Zheng R, Zeng H, Zhang S and He J:
Annual report on status of cancer in China, 2011. Chin J Cancer
Res. 27:2–12. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang H, Chen Y and Wu G: SDHB deficiency
promotes TGFβ-mediated invasion and metastasis of colorectal cancer
through transcriptional repression complex SNAIL1-SMAD3/4. Transl
Oncol. 9:512–520. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jin XQ, Liu P and Zhang QP: [Genetic
susceptibility in children with incomplete Kawasaki disease.
Zhongguo Dang Dai Er Ke Za Zhi. 17:663–667. 2015.PubMed/NCBI
|
|
4
|
Segal NH and Saltz LB: Evolving treatment
of advanced colon cancer. Annu Rev Med. 60:207–219. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Misale S, Di Nicolantonio F,
Sartore-Bianchi A, Siena S and Bardelli A: Resistance to anti-EGFR
therapy in colorectal cancer: From heterogeneity to convergent
evolution. Cancer Discov. 4:1269–1280. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Misale S, Yaeger R, Hobor S, Scala E,
Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M,
Siravegna G, et al: Emergence of KRAS mutations and acquired
resistance to anti-EGFR therapy in colorectal cancer. Nature.
486:532–536. 2012.PubMed/NCBI
|
|
7
|
Opal P, Garcia JJ, McCall AE, Xu B, Weeber
EJ, Sweatt JD, Orr HT and Zoghbi HY: Generation and
characterization of LANP/pp32 null mice. Mol Cell Biol.
24:3140–3149. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Adegbola O and Pasternack GR:
Phosphorylated retinoblastoma protein complexes with pp32 and
inhibits pp32-mediated apoptosis. J Biol Chem. 280:15497–15502.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Williams TK, Costantino CL, Bildzukewicz
NA, Richards NG, Rittenhouse DW, Einstein L, Cozzitorto JA, Keen
JC, Dasgupta A, Gorospe M, et al: pp32 (ANP32A) expression inhibits
pancreatic cancer cell growth and induces gemcitabine resistance by
disrupting HuR binding to mRNAs. PLoS One. 5:e154552010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brody JR, Kadkol SS, Hauer MC, Rajaii F,
Lee J and Pasternack GR: pp32 reduction induces differentiation of
TSU-Pr1 cells. Am J Pathol. 164:273–283. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang S, Wang Y, Lu Q, Liu X, Wang F, Ma X,
Cui C, Shi C, Li J and Zhang D: The expression and distributions of
ANP32A in the developing brain. Biomed Res Int.
2015:2073472015.PubMed/NCBI
|
|
12
|
Pan W, da Graca LS, Shao Y, Yin Q, Wu H
and Jiang X: PHAPI/pp32 suppresses tumorigenesis by stimulating
apoptosis. J Biol Chem. 284:6946–6954. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schramedei K, Mörbt N, Pfeifer G, Läuter
J, Rosolowski M, Tomm JM, von Bergen M, Horn F and Brocke-Heidrich
K: MicroRNA-21 targets tumor suppressor genes ANP32A and SMARCA4.
Oncogene. 30:2975–2985. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mazroui R, Di Marco S, Clair E, von Roretz
C, Tenenbaum SA, Keene JD, Saleh M and Gallouzi IE:
Caspase-mediated cleavage of HuR in the cytoplasm contributes to
pp32/PHAP-I regulation of apoptosis. J Cell Biol. 180:113–127.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li C, Ruan HQ, Liu YS, Xu MJ, Dai J, Sheng
QH, Tan YX, Yao ZZ, Wang HY, Wu JR, et al: Quantitative proteomics
reveal up-regulated protein expression of the SET complex
associated with hepatocellular carcinoma. J Proteome Res.
11:871–885. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Velmurugan BK, Yeh K-T, Lee C-H, Lin SH,
Chin MC, Chiang SL, Wang ZH, Hua CH, Tsai MH, Chang JG, et al:
Acidic leucine-rich nuclear phosphoprotein-32A (ANP32A) association
with lymph node metastasis predicts poor survival in oral squamous
cell carcinoma patients. Oncotarget. 7:10879–10890. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li M, Makkinje A and Damuni Z: Molecular
identification of I1PP2A, a novel potent
heat-stable inhibitor protein of protein phosphatase 2A.
Biochemistry. 35:6998–7002. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schönthal AH: Role of serine/threonine
protein phosphatase 2A in cancer. Cancer Lett. 170:1–13. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Grethe S and Pörn-Ares MI: p38 MAPK
regulates phosphorylation of Bad via PP2A-dependent suppression of
the MEK1/2-ERK1/2 survival pathway in TNF-alpha induced endothelial
apoptosis. Cell Signal. 18:531–540. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Meng G, Sun Y, Fu W, Guo Z and Xu L:
Microcystin-LR induces cytoskeleton system reorganization through
hyperphosphorylation of tau and HSP27 via PP2A inhibition and
subsequent activation of the p38 MAPK signaling pathway in
neuroendocrine (PC12) cells. Toxicology. 290:218–229. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Garcia A, Cayla X, Guergnon J, Dessauge F,
Hospital V, Rebollo MP, Fleischer A and Rebollo A: Serine/threonine
protein phosphatases PP1 and PP2A are key players in apoptosis.
Biochimie. 85:721–726. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Boudreau RT, Conrad DM and Hoskin DW:
Apoptosis induced by protein phosphatase 2A (PP2A) inhibition in T
leukemia cells is negatively regulated by PP2A-associated p38
mitogen-activated protein kinase. Cell Signal. 19:139–151. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shang C and Huang S: PP2A level in
colorectal cancer cells predicts the response of p38 targeted
therapy. EBioMedicine. 2:1848–1849. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gupta J, del Barco Barrantes I, Igea A,
Sakellariou S, Pateras IS, Gorgoulis VG and Nebreda AR: Dual
function of p38α MAPK in colon cancer: Suppression of
colitis-associated tumor initiation but requirement for cancer cell
survival. Cancer Cell. 25:484–500. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wagner EF and Nebreda AR: Signal
integration by JNK and p38 MAPK pathways in cancer development. Nat
Rev Cancer. 9:537–549. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kumar A, Pandurangan AK, Lu F, Fyrst H,
Zhang M, Byun HS, Bittman R and Saba JD: Chemopreventive
sphingadienes downregulate Wnt signaling via a PP2A/Akt/GSK3β
pathway in colon cancer. Carcinogenesis. 33:1726–1735. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Smith RA, Andrews K, Brooks D, DeSantis
CE, Fedewa SA, Lortet-Tieulent J, Manassaram-Baptiste D, Brawley OW
and Wender RC: Cancer screening in the United States, 2016: A
review of current American Cancer Society guidelines and current
issues in cancer screening. CA Cancer J Clin. 66:96–114. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Okugawa Y, Grady WM and Goel A: Epigenetic
alterations in colorectal cancer: Emerging biomarkers.
Gastroenterology. 149:1204–1225.e12. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bae JM, Kim JH and Kang GH: Epigenetic
alterations in colorectal cancer: The CpG island methylator
phenotype. Histol Histopathol. 28:585–595. 2013.PubMed/NCBI
|
|
30
|
Weng KP, Hsieh KS, Huang SH, Wu HW, Chien
JH, Lin CC, Tang CW, Ou SF, Huang SJ and Ger LP: Myeloperoxidase
genetic polymorphisms and susceptibility to Kawasaki disease in
Taiwanese children. J Microbiol Immunol Infect. 49:788–796. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bai J, Brody JR, Kadkol SS and Pasternack
GR: Tumor suppression and potentiation by manipulation of pp32
expression. Oncogene. 20:2153–2160. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li W, Chen Z, Gong FR, Zong Y, Chen K, Li
DM, Yin H, Duan WM, Miao Y, Tao M, et al: Growth of the pancreatic
cancer cell line PANC-1 is inhibited by protein phosphatase 2A
inhibitors through overactivation of the c-Jun N-terminal kinase
pathway. Eur J Cancer. 47:2654–2664. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Schafer ZT, Parrish AB, Wright KM,
Margolis SS, Marks JR, Deshmukh M and Kornbluth S: Enhanced
sensitivity to cytochrome c-induced apoptosis mediated by
PHAPI in breast cancer cells. Cancer Res. 66:2210–2218. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kadkol SS, El Naga GA, Brody JR, Bai J,
Gusev Y, Dooley WC and Pasternack GR: Expression of pp32 gene
family members in breast cancer. Breast Cancer Res Treat. 68:65–73.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hill MM, Adrain C, Duriez PJ, Creagh EM
and Martin SJ: Analysis of the composition, assembly kinetics and
activity of native Apaf-1 apoptosomes. EMBO J. 23:2134–2145. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kim HE, Jiang X, Du F and Wang X: PHAPI,
CAS, and Hsp70 promote apoptosome formation by preventing Apaf-1
aggregation and enhancing nucleotide exchange on Apaf-1. Mol Cell.
30:239–247. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hoffarth S, Zitzer A, Wiewrodt R, Hähnel
PS, Beyer V, Kreft A, Biesterfeld S and Schuler M: pp32/PHAPI
determines the apoptosis response of non-small-cell lung cancer.
Cell Death Differ. 15:161–170. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Brody JR, Witkiewicz A, Williams TK,
Kadkol SS, Cozzitorto J, Durkan B, Pasternack GR and Yeo CJ:
Reduction of pp32 expression in poorly differentiated pancreatic
ductal adenocarcinomas and intraductal papillary mucinous neoplasms
with moderate dysplasia. Mod Pathol. 20:1238–1244. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shi H, Hood KA, Hayes MT and Stubbs RS:
Proteomic analysis of advanced colorectal cancer by laser capture
microdissection and two-dimensional difference gel electrophoresis.
J Proteomics. 75:339–351. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pekarčíková L, Knopfová L, Beneš P and
Šmarda J: c-Myb regulates NOX1/p38 to control survival of
colorectal carcinoma cells. Cell Signal. 28:924–936. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li H, Huang K, Gao L, Wang L, Niu Y, Liu
H, Wang Z, Wang L, Wang G and Wang J: TES inhibits colorectal
cancer progression through activation of p38. Oncotarget.
7:45819–45836. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Fassetta M, D'Alessandro L, Coltella N, Di
Renzo MF and Rasola A: Hepatocyte growth factor installs a survival
platform for colorectal cancer cell invasive growth and overcomes
p38 MAPK-mediated apoptosis. Cell Signal. 18:1967–1976. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang J, Huang F, Bai Z, Chi B, Wu J and
Chen X: Curcumol inhibits growth and induces apoptosis of
colorectal cancer LoVo cell line via IGF-1R and p38 MAPK pathway.
Int J Mol Sci. 16:19851–19867. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yu LG, Packman LC, Weldon M, Hamlett J and
Rhodes JM: Protein phosphatase 2A, a negative regulator of the ERK
signaling pathway, is activated by tyrosine phosphorylation of
putative HLA class II-associated protein I (PHAPI)/pp32 in response
to the antiproliferative lectin, jacalin. J Biol Chem.
279:41377–41383. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang Z, Yang H, Tachado SD, Capó-Aponte
JE, Bildin VN, Koziel H and Reinach PS: Phosphatase-mediated
crosstalk control of ERK and p38 MAPK signaling in corneal
epithelial cells. Invest Ophthalmol Vis Sci. 47:5267–5275. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Meng G, Wang W, Chai K, Yang S, Li F and
Jiang K: Combination treatment with triptolide and
hydroxycamptothecin synergistically enhances apoptosis in A549 lung
adenocarcinoma cells through PP2A-regulated ERK, p38 MAPKs and Akt
signaling pathways. Int J Oncol. 46:1007–1017. 2015.PubMed/NCBI
|
|
47
|
Habrukowich C, Han DK, Le A, Rezaul K, Pan
W, Ghosh M, Li Z, Dodge-Kafka K, Jiang X, Bittman R, et al:
Sphingosine interaction with acidic leucine-rich nuclear
phosphoprotein-32A (ANP32A) regulates PP2A activity and
cyclooxygenase (COX)-2 expression in human endothelial cells. J
Biol Chem. 285:26825–26831. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Da Silva M, Jaggers GK, Verstraeten SV,
Erlejman AG, Fraga CG and Oteiza PI: Large procyanidins prevent
bile-acid-induced oxidant production and membrane-initiated ERK1/2,
p38, and Akt activation in Caco-2 cells. Free Radic Biol Med.
52:151–159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Johnson SM, Gulhati P, Rampy BA, Han Y,
Rychahou PG, Doan HQ, Weiss HL and Evers BM: Novel expression
patterns of PI3K/Akt/mTOR signaling pathway components in
colorectal cancer. J Am Coll Surg. 210:767–776, 776–768. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chen B, Zeng X, He Y, Wang X, Liang Z, Liu
J, Zhang P, Zhu H, Xu N and Liang S: STC2 promotes the
epithelial-mesenchymal transition of colorectal cancer cells
through AKT-ERK signaling pathways. Oncotarget. 7:71400–71416.
2016.PubMed/NCBI
|
|
51
|
Baba Y, Nosho K, Shima K, Hayashi M,
Meyerhardt JA, Chan AT, Giovannucci E, Fuchs CS and Ogino S:
Phosphorylated AKT expression is associated with PIK3CA
mutation, low stage, and favorable outcome in 717 colorectal
cancers. Cancer. 117:1399–1408. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Van Kanegan MJ, Adams DG, Wadzinski BE and
Strack S: Distinct protein phosphatase 2A heterotrimers modulate
growth factor signaling to extracellular signal-regulated kinases
and Akt. J Biol Chem. 280:36029–36036. 2005. View Article : Google Scholar : PubMed/NCBI
|
